Eli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds
Eli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds
Friday, Eli Lilly And Company (NYSE:LLY) announced it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing its total investment from $3.7 billion to $9 billion.
週五，禮來公司（紐約證券交易所代碼：LLY）宣佈，其對印第安納州黎巴嫩製造基地的投資翻了一番多，新的承諾爲53億美元，總投資從37億美元增加到90億美元。
This expansion will enhance Lilly's capacity to manufacture active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injection.
此次擴張將增強禮來公司爲Zepbound（替塞帕肽）注射劑和Mounjaro（替塞帕肽）注射劑生產活性藥物成分（API）的能力。
Related: Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma.
相關： 禮來收購Nexus Pharma的製造工廠，旨在縮小Zepbound/Mounjaro的供需缺口。
Since 2020, Lilly has committed more than $16 billion to develop new U.S. and European manufacturing sites.
自2020年以來，禮來已承諾超過160億美元用於開發新的美國和歐洲製造基地。
New locations outside Indiana include Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and Alzey, Germany.
印第安納州以外的新地點包括北卡羅來納州的三角研究園和康科德、愛爾蘭的利默里克和德國的阿爾齊。
Separately, the company has invested an additional $1.2 billion to update existing manufacturing facilities in Indianapolis and recently acquired an injectable manufacturing facility in Pleasant Prairie, Wisconsin, from Nexus Pharmaceuticals.
另外，該公司還額外投資了12億美元更新印第安納波利斯的現有製造工廠，最近還從Nexus Pharmicals手中收購了位於威斯康星州普萊森特普雷裏的注射劑製造工廠。
Together, these manufacturing investments total more than $18 billion.
這些製造業投資總額超過180億美元。
"Today's announcement tops the largest manufacturing investment in our company's history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in U.S. history," said David Ricks, Lilly's chair and CEO.
禮來公司董事長兼首席執行官戴維·裏克斯表示：“今天的公告是我們公司歷史上最大的製造業投資，我們認爲，這是美國曆史上對合成藥物API製造的最大一筆投資。”
As part of this additional investment in the Lebanon site, located within Indiana's LEAP Research and Innovation District, Lilly expects to add 200 full-time jobs for highly skilled workers such as engineers, scientists, operating personnel and lab technicians, resulting in an estimated 900 full-time employees when the facility is fully operational.
作爲對位於印第安納州LEAP研究與創新區的黎巴嫩基地的額外投資的一部分，禮來公司預計將爲工程師、科學家、操作人員和實驗室技術人員等高技能工人增加200個全職工作崗位，使該設施全面投入運營後估計將增加900名全職員工。
Additionally, there will be more than 5,000 construction jobs during the site's development.
此外，在場地開發期間，將有超過5,000個建築工作崗位。
In May 2022, Lilly first announced its plans to invest $2.1 billion and create up to 500 new jobs at LEAP.
2022年5月，禮來首次宣佈計劃在LEAP投資21億美元並創造多達500個新工作崗位。
At the company's Lebanon groundbreaking in April 2023, Lilly announced an additional $1.6 billion investment and 200 new jobs at the site.
在2023年4月該公司在黎巴嫩的破土動工儀式上，禮來公司宣佈再投資16億美元，並在該基地新增200個工作崗位。
Eli Lilly expects to begin making medicines in Lebanon toward the end of 2026 – with operations scaling up through 2028.
禮來公司預計將於2026年底開始在黎巴嫩生產藥品，業務規模將擴大到2028年。
Price Action: LLY shares are up 0.09% at $809.14 at the last check on Friday.
價格走勢：在週五的最後一次支票中，LLY股價上漲0.09％，至809.14美元。
Image by Mohammed_Al_Ali via Shutterstock
圖片由 Mohammed_Al_Ali 通過 Shutterstock 拍攝